{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:53:40Z","timestamp":1792270420093,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["ME 3696\/3-1"],"award-info":[{"award-number":["ME 3696\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prader\u2013Willi syndrome (PWS) is a rare neurodevelopmental disorder based on a loss of paternally expressed genes in chromosome segment 15q11-13. Behavioral traits such as temper outbursts, stereotypic, and ritualistic behavior, as well as an increased risk of psychosis accompany the syndrome, representing a major issue in the treatment of adults with PWS. Up to now, no treatment guideline for these conditions in PWS exist. This study aimed to retrospectively analyze the effect and adverse effects of treatment with aripiprazole for temper outbursts in 10 adults with PWS.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Aripiprazole was prescribed for temper outbursts (n\u2009=\u200910). Treatment outcome was assessed using the Clinical Global Impression-Severity (CGI-S) and -Improvement Scale (CGI-I).<\/jats:p>\n                <jats:p>Treatment success (CGI-I\u2009&lt;\u20093) was observed in 70% of cases, with adverse effects from mild to partly serious extent in 60% of cases. The major adverse effect observed was increased daytime sleepiness. In total, 50% of the individuals were treated successfully for temper outbursts. The BMI did not change significantly in the successfully treated group after 6\u00a0months of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Aripiprazole can be a treatment option for temper outbursts in people with PWS. Although a high rate of side effects was detected, their severity led to discontinuation in only 20% of the cases. Furthermore, the absence of weight gain makes aripiprazole interesting especially for the PWS population.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02470-y","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T12:02:55Z","timestamp":1661515375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Aripiprazole treatment for temper outbursts in Prader\u2013Willi syndrome"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8759-8660","authenticated-orcid":false,"given":"Maximilian","family":"Deest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelte","family":"Wieting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian Michael","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Deest-Gaubatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Groh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Frieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Eberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"issue":"4","key":"2470_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1573396315666190716120925","volume":"15","author":"MG Butler","year":"2019","unstructured":"Butler MG, Miller JL, Forster JL. Prader\u2013Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update. Curr Pediatr Rev. 2019;15(4):207\u201344.","journal-title":"Curr Pediatr Rev"},{"issue":"16","key":"2470_CR2","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/ajmg.a.32364","volume":"146","author":"B Horsthemke","year":"2008","unstructured":"Horsthemke B, Wagstaff J. Mechanisms of imprinting of the Prader\u2013Willi\/Angelman region. Am J Med Genet Part A. 2008;146(16):2041\u201352.","journal-title":"Am J Med Genet Part A"},{"key":"2470_CR3","first-page":"1","volume":"2019","author":"JL Miller","year":"2018","unstructured":"Miller JL, van Wattum PJ, Brokamp E, Fairbrother L, Scheimann A, Shoemaker AH, et al. A multidisciplinary approach to the clinical management of Prader\u2013Willi syndrome. Mol Genet Genomic Med. 2018;2019:1\u201321.","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"2470_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","volume":"14","author":"SB Cassidy","year":"2012","unstructured":"Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader\u2013Willi syndrome. Genet Med. 2012;14(1):10\u201326.","journal-title":"Genet Med"},{"issue":"7","key":"2470_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jne.12728","volume":"31","author":"M Tauber","year":"2019","unstructured":"Tauber M, Coupaye M, Diene G, Molinas C, Valette M, Beauloye V. Prader\u2013Willi syndrome: a model for understanding the ghrelin system. J Neuroendocrinol. 2019;31(7):1\u201313.","journal-title":"J Neuroendocrinol"},{"issue":"12","key":"2470_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40618-015-0312-9","volume":"38","author":"MA Angulo","year":"2015","unstructured":"Angulo MA, Butler MG, Cataletto ME. Prader\u2013Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest. 2015;38(12):1249\u201363.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2470_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00023210-200317030-00003","volume":"17","author":"E Dykens","year":"2003","unstructured":"Dykens E, Shah B. Psychiatric Disorders in Prader\u2013Willi Syndrome. CNS Drugs. 2003;17(3):167\u201378.","journal-title":"CNS Drugs"},{"issue":"1","key":"2470_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2788.2004.00582.x","volume":"48","author":"HC Steinhausen","year":"2004","unstructured":"Steinhausen HC, Eiholzer U, Hauffa BP, Malin Z. Behavioural and emotional disturbances in people with Prader\u2013Willi syndrome. J Intellect Disabil Res. 2004;48(1):47\u201352.","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"2470_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2788.2006.00895.x","volume":"51","author":"S Soni","year":"2007","unstructured":"Soni S, Whittington J, Holland AJ, Webb T, Maina E, Boer H, et al. The course and outcome of psychiatric illness in people with Prader\u2013Willi syndrome: Implications for management and treatment. J Intellect Disabil Res. 2007;51(1):32\u201342.","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"2470_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1017\/S0033291702006736","volume":"33","author":"AJ Holland","year":"2003","unstructured":"Holland AJ, Whittington JE, Butler J, Webb T, Boer H, Clarke D. Behavioral phenotypes associated with specific genetic disorders: evidence from a population-based study of people with Prader\u2013Willi syndrome. Psychol Med. 2003;33(1):141\u201353.","journal-title":"Psychol Med"},{"issue":"10","key":"2470_CR11","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1017\/S0033291707002504","volume":"38","author":"S Soni","year":"2008","unstructured":"Soni S, Whittington J, Holland AJ, Webb T, Maina EN, Boer H, et al. The phenomenology and diagnosis of psychiatric illness in people with Prader\u2013Willi syndrome. Psychol Med. 2008;38(10):1505\u201314.","journal-title":"Psychol Med"},{"issue":"2","key":"2470_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/jir.12707","volume":"64","author":"SM Feighan","year":"2020","unstructured":"Feighan SM, Hughes M, Maunder K, Roche E, Gallagher L. A profile of mental health and behaviour in Prader\u2013Willi syndrome. J Intellect Disabil Res. 2020;64(2):158\u201369.","journal-title":"J Intellect Disabil Res"},{"issue":"3","key":"2470_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/cge.13142","volume":"93","author":"AM Manzardo","year":"2018","unstructured":"Manzardo AM, Weisensel N, Ayala S, Hossain W, Butler MG. Prader\u2013Willi syndrome genetic subtypes and clinical neuropsychiatric diagnoses in residential care adults. Clin Genet. 2018;93(3):622\u201331.","journal-title":"Clin Genet"},{"issue":"1","key":"2470_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11689-017-9200-2","volume":"9","author":"EM Dykens","year":"2017","unstructured":"Dykens EM, Roof E, Hunt-Hawkins H, Dankner N, Lee EB, Shivers CM, et al. Diagnoses and characteristics of autism spectrum disorders in children with Prader\u2013Willi syndrome. J Neurodev Disord. 2017;9(1):1\u201312.","journal-title":"J Neurodev Disord"},{"issue":"1","key":"2470_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/jmg.40.1.72","volume":"40","author":"A Vogels","year":"2003","unstructured":"Vogels A, Matthijs G, Legius E, Devriendt K, Fryns JP. Chromosome 15 maternal uniparental disomy and psychosis in Prader\u2013Willi syndrome [7]. J Med Genet. 2003;40(1):72\u20133.","journal-title":"J Med Genet"},{"issue":"9","key":"2470_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2788.2012.01634.x","volume":"57","author":"MM Mazaheri","year":"2013","unstructured":"Mazaheri MM, Rae-Seebach RD, Preston HE, Schmidt M, Kountz-Edwards S, Field N, et al. The impact of Prader\u2013Willi syndrome on the family\u2019s quality of life and caregiving, and the unaffected siblings\u2019 psychosocial adjustment. J Intellect Disabil Res. 2013;57(9):861\u201373.","journal-title":"J Intellect Disabil Res"},{"issue":"3","key":"2470_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1352\/1944-7558-117.3.207","volume":"117","author":"S Lanfranchi","year":"2012","unstructured":"Lanfranchi S, Vianello R. Stress, locus of control, and family cohesion and adaptability in parents of children with down, williams, fragile x, and Prader\u2013Willi syndromes. Am J Intellect Dev Disabil. 2012;117(3):207\u201324.","journal-title":"Am J Intellect Dev Disabil"},{"issue":"1","key":"2470_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00431-015-2670-x","volume":"175","author":"O Bonnot","year":"2015","unstructured":"Bonnot O, Cohen D, Thuilleaux D, Consoli A, Cabal S, Tauber M. Psychotropic treatments in Prader\u2013Willi syndrome: a critical review of published literature. Eur J Pediatr. 2015;175(1):9\u201318.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"2470_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1034\/j.1600-0447.2000.102006461.x","volume":"102","author":"R Durst","year":"2000","unstructured":"Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. Risperidone in treating behavioural disturbances of Prader\u2013Willi syndrome. Acta Psychiatr Scand. 2000;102(6):461\u20135.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"2470_CR20","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1111\/j.1442-200X.2009.02996.x","volume":"52","author":"S Araki","year":"2010","unstructured":"Araki S, Ohji T, Shiota N, Dobashi K, Shimono M, Shirahata A. Successful risperidone treatment for behavioral disturbances in Prader\u2013Willi syndrome. Pediatr Int. 2010;52(1):2009\u201311.","journal-title":"Pediatr Int"},{"issue":"6","key":"2470_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1046\/j.1365-2788.1998.4260440.x","volume":"42","author":"D Clarke","year":"1998","unstructured":"Clarke D, Boer H, Webb T, Scott P, Frazer S, Vogels A, et al. Prader\u2013Willi syndrome and psychotic symptoms: I. Case descriptions and genetic studies. J Intellect Disabil Res. 1998;42(6):440\u201350. https:\/\/doi.org\/10.1046\/j.1365-2788.1998.4260440.x.","journal-title":"J Intellect Disabil Res"},{"issue":"5","key":"2470_CR22","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/JCP.0000000000000566","volume":"36","author":"\u00d6F Ak\u00e7a","year":"2016","unstructured":"Ak\u00e7a \u00d6F, Yilmaz S. Aripiprazole in the treatment of obsessive compulsive disorder and aggressive behaviors in a child with prader willi syndrome. J Clin Psychopharmacol. 2016;36(5):526\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2470_CR23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.9758\/cpn.2018.16.4.497","volume":"16","author":"W Briegel","year":"2018","unstructured":"Briegel W. Clinical usefulness of aripiprazole treatment in a girl with Prader\u2013Willi syndrome and psychosis. Clin Psychopharmacol Neurosci. 2018;16(4):497\u2013500.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"7","key":"2470_CR24","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.4103\/psychiatry.IndianJPsychiatry_526_18","volume":"61","author":"A Thamby","year":"2019","unstructured":"Thamby A, Jaisoorya TS. Antipsychotic augmentation in the treatment of obsessive-compulsive disorder. Indian J Psychiatry. 2019;61(7):S51\u20137.","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"2470_CR25","doi-asserted-by":"publisher","first-page":"e2686","DOI":"10.1002\/hup.2686","volume":"34","author":"V Brakoulias","year":"2019","unstructured":"Brakoulias V, Starcevic V, Albert U, Arumugham SS, Bailey BE, Belloch A, et al. Treatments used for obsessive\u2013compulsive disorder\u2014An international perspective. Hum Psychopharmacol. 2019;34(1):e2686.","journal-title":"Hum Psychopharmacol"},{"key":"2470_CR26","first-page":"2635","volume":"11","author":"G Di Sciascio","year":"2015","unstructured":"Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015;11:2635\u201347.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"2470_CR27","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400\u201311.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"2470_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14737175.2016.1211007","volume":"16","author":"R Rizzo","year":"2016","unstructured":"Rizzo R, Pavone P. Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders. Expert Rev Neurother. 2016;16(8):867\u201374.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"2470_CR29","first-page":"35","volume":"50","author":"K Kontoangelos","year":"2020","unstructured":"Kontoangelos K, Lazaratou E, Economou M, Yiannopoulou KG, Papageorgiou CC. Efficacy of low-dose aripiprazole for treatment of psychotic symptoms in a patient with 22q11.2 deletion syndrome. Psychopharmacol Bull. 2020;50(1):35\u20139.","journal-title":"Psychopharmacol Bull"},{"key":"2470_CR30","first-page":"125","volume":"1","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical global impression (CGI). ECDEU Assess Man Psychopharmacol. 1976;1:125\u20136.","journal-title":"ECDEU Assess Man Psychopharmacol"},{"key":"2470_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/NDT.S5560","volume":"6","author":"A Dimitropoulos","year":"2010","unstructured":"Dimitropoulos A. Clinical management of behavioral characteristics of Prader&ndash; Willi syndrome. Neuropsychiatr Dis Treat. 2010;6:107.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"2470_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jir.12831","volume":"65","author":"J Wieting","year":"2021","unstructured":"Wieting J, Eberlein C, Bleich S, Frieling H, Deest M. Behavioural change in Prader\u2013Willi syndrome during COVID\u201019 pandemic. J Intellect Disabil Res. 2021;65(7):609\u201316. https:\/\/doi.org\/10.1111\/jir.12831.","journal-title":"J Intellect Disabil Res"},{"issue":"2","key":"2470_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/00004583-199103000-00020","volume":"30","author":"B Dech","year":"1991","unstructured":"Dech B, Budow L. The use of fluoxetine in an adolescent with Prader\u2013Willi Syndrome. J Am Acad Child Adolesc Psychiatry. 1991;30(2):298\u2013302. https:\/\/doi.org\/10.1097\/00004583-199103000-00020.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"2470_CR34","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1097\/00004583-199307000-00025","volume":"32","author":"E Benjamin","year":"1993","unstructured":"Benjamin E, Buot-Smith T. Naltrexone and fluoxetine in Prader\u2013Willi Syndrome. J Am Acad Child Adolesc Psychiatry. 1993;32(4):870\u20133.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"2470_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1352\/0895-8017(2004)109<301:EOTIAW>2.0.CO;2","volume":"109","author":"NA Shapira","year":"2004","unstructured":"Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ. Effects of topiramate in adults with Prader\u2013Willi syndrome. Am J Ment Retard. 2004;109(4):301\u20139.","journal-title":"Am J Ment Retard"},{"issue":"2","key":"2470_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0887-8994(02)00490-3","volume":"28","author":"SA Smathers","year":"2003","unstructured":"Smathers SA, Wilson JG, Nigro MA. Topiramate effectiveness in Prader\u2013Willi syndrome. Pediatr Neurol. 2003;28(2):130\u20133.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"2470_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/eat.1062","volume":"30","author":"Y Kohn","year":"2001","unstructured":"Kohn Y, Weizman A, Apter A. Aggravation of food-related behavior in an adolescent with Prader\u2013Willi Syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord. 2001;30(1):113\u20137.","journal-title":"Int J Eat Disord"},{"issue":"3","key":"2470_CR38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajmg.a.62041","volume":"185","author":"M Deest","year":"2020","unstructured":"Deest M, Jakob MM, Seifert J, Bleich S, Frieling H, Eberlein C. Sertraline as a treatment option for temper outbursts in Prader\u2013Willi syndrome. Am J Med Genet Part A. 2020;185(3):790\u20137. https:\/\/doi.org\/10.1002\/ajmg.a.62041.","journal-title":"Am J Med Genet Part A"},{"issue":"2","key":"2470_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes12020152","volume":"12","author":"J Forster","year":"2021","unstructured":"Forster J, Duis J, Butler MG. Pharmacogenetic testing of cytochrome P450 drug metabolizing enzymes in a case series of patients with Prader\u2013Willi syndrome. Genes (Basel). 2021;12(2):1\u201330.","journal-title":"Genes (Basel)"},{"issue":"18","key":"2470_CR40","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1093\/hmg\/ddz100","volume":"28","author":"JR Davies","year":"2019","unstructured":"Davies JR, Wilkinson LS, Isles AR, Humby T. Prader\u2013Willi syndrome imprinting centre deletion mice have impaired baseline and 5-HT2CR-mediated response inhibition. Hum Mol Genet. 2019;28(18):3013\u201323.","journal-title":"Hum Mol Genet"},{"key":"2470_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1101\/sqb.2006.71.024","volume":"71","author":"S Kishore","year":"2006","unstructured":"Kishore S, Stamm S. Regulation of alternative splicing by snoRNAs. Cold Spring Harb Symp Quant Biol. 2006;71:329\u201334.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2470_CR42","first-page":"329","volume":"274","author":"T Kikuchi","year":"1995","unstructured":"Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S. (OPC-1 4597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995;274:329\u201336.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02470-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02470-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02470-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:02:29Z","timestamp":1661558549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02470-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2470"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02470-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the Declaration of Helsinki and was approved by the local Ethics Committee of Hannover Medical School (NR. 8129_BO_S_2020). All participants in this study were informed and gave their written consent for participation and publication of results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MD, JW, SD, HF and SB declare, that they do not have any conflicts of interest to declare. JS took part in an educational event sponsored by Otsuka\/Lundbeck. CE has received speaker\u00b4s honoraria from Recordati Pharma GmbH. ST is a member of the advisory board for Otsuka and Janssen-Cilag and has received speaker\u00b4s honoraria from Janssen-Cilag, Lundbeck\/Otsuka, Recordati Pharma GmbH, and Servier.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"324"}}